Background: In August 2020, Sputnik V was registered as Gam-COVID-Vac by the Russian Ministry of Health, and since December 2020 it has been distributed in 61 countries worldwide. On 25 February 2021, the Republic of San Marino started its vaccination campaign, which includes Sputnik V. Our aim was to describe the adverse events following immunization (AEFIs) with this vaccine through participant-based active surveillance in the country. Methods: Beginning from 4 March to 8 April 2021, a nationwide study was conducted on San Marino's population aged 18–89 years who received one or two doses of Sputnik V. E-questionnaire dissemination occurred through e-mails, QR-codes or live/phone interviews ~7 days after the first and second vaccine dose. A descriptive analysis was conducted to quantify AEFI incidence on both occasions, stratifying results by type and severity of symptoms. Findings: Mean age of the 2558 vaccine recipients was 66±14 years. First-dose AEFI incidence was 53.3% (systemic reactions at 42.2%), while second-dose AEFI incidence was 66.8% (systemic reactions at 50.4%) (n = 1288). In general, 76.0% of two-dose recipients reported some AEFIs after either vaccine dose, and 2.1% suffered severe reactions; in 60- to 89-year-olds (n = 1021), AEFI incidence was 70.0%, with 53.0% of subjects describing systemic reactions and 0.8% reporting severe symptoms. The most frequent symptoms were local pain, asthenia, headache and joint pain. Interpretation: Our results, albeit preliminary, suggest that Sputnik V has a high tolerability profile in the population aged ≥60 years in terms of short-term AEFIs. Funding: None.

ROCCA observational study: Early results on safety of Sputnik V vaccine (Gam-COVID-Vac) in the Republic of San Marino using active surveillance / Montalti M.; Solda' G.; Di Valerio Z.; Salussolia A.; Lenzi J.; Forcellini M.; Barvas E.; Guttmann S.; Messina R.; Poluzzi E.; Raschi E.; Riccardi R.; Fantini M.P.; La Fauci G.; Gori D.. - In: ECLINICALMEDICINE. - ISSN 2589-5370. - ELETTRONICO. - 38:(2021), pp. 101027.1-101027.7. [10.1016/j.eclinm.2021.101027]

ROCCA observational study: Early results on safety of Sputnik V vaccine (Gam-COVID-Vac) in the Republic of San Marino using active surveillance

Montalti M.;Solda' G.;Salussolia A.
;
Lenzi J.;Messina R.;Poluzzi E.;Raschi E.;Fantini M. P.;La Fauci G.;Gori D.
2021

Abstract

Background: In August 2020, Sputnik V was registered as Gam-COVID-Vac by the Russian Ministry of Health, and since December 2020 it has been distributed in 61 countries worldwide. On 25 February 2021, the Republic of San Marino started its vaccination campaign, which includes Sputnik V. Our aim was to describe the adverse events following immunization (AEFIs) with this vaccine through participant-based active surveillance in the country. Methods: Beginning from 4 March to 8 April 2021, a nationwide study was conducted on San Marino's population aged 18–89 years who received one or two doses of Sputnik V. E-questionnaire dissemination occurred through e-mails, QR-codes or live/phone interviews ~7 days after the first and second vaccine dose. A descriptive analysis was conducted to quantify AEFI incidence on both occasions, stratifying results by type and severity of symptoms. Findings: Mean age of the 2558 vaccine recipients was 66±14 years. First-dose AEFI incidence was 53.3% (systemic reactions at 42.2%), while second-dose AEFI incidence was 66.8% (systemic reactions at 50.4%) (n = 1288). In general, 76.0% of two-dose recipients reported some AEFIs after either vaccine dose, and 2.1% suffered severe reactions; in 60- to 89-year-olds (n = 1021), AEFI incidence was 70.0%, with 53.0% of subjects describing systemic reactions and 0.8% reporting severe symptoms. The most frequent symptoms were local pain, asthenia, headache and joint pain. Interpretation: Our results, albeit preliminary, suggest that Sputnik V has a high tolerability profile in the population aged ≥60 years in terms of short-term AEFIs. Funding: None.
2021
ROCCA observational study: Early results on safety of Sputnik V vaccine (Gam-COVID-Vac) in the Republic of San Marino using active surveillance / Montalti M.; Solda' G.; Di Valerio Z.; Salussolia A.; Lenzi J.; Forcellini M.; Barvas E.; Guttmann S.; Messina R.; Poluzzi E.; Raschi E.; Riccardi R.; Fantini M.P.; La Fauci G.; Gori D.. - In: ECLINICALMEDICINE. - ISSN 2589-5370. - ELETTRONICO. - 38:(2021), pp. 101027.1-101027.7. [10.1016/j.eclinm.2021.101027]
Montalti M.; Solda' G.; Di Valerio Z.; Salussolia A.; Lenzi J.; Forcellini M.; Barvas E.; Guttmann S.; Messina R.; Poluzzi E.; Raschi E.; Riccardi R.; Fantini M.P.; La Fauci G.; Gori D.
File in questo prodotto:
File Dimensione Formato  
Montalti-2021-EClinicalMedicine.pdf

accesso aperto

Tipo: Versione (PDF) editoriale
Licenza: Creative commons
Dimensione 891.87 kB
Formato Adobe PDF
891.87 kB Adobe PDF Visualizza/Apri
mmc2.zip

accesso aperto

Tipo: File Supplementare
Licenza: Licenza per Accesso Aperto. Altra tipologia di licenza compatibile con Open Access
Dimensione 461.09 kB
Formato Zip File
461.09 kB Zip File Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/850494
Citazioni
  • ???jsp.display-item.citation.pmc??? 28
  • Scopus 36
  • ???jsp.display-item.citation.isi??? 28
social impact